232
Participants
Start Date
August 22, 2012
Primary Completion Date
February 5, 2015
Study Completion Date
February 5, 2015
AGN-195263 0.1%
1 drop of AGN-195263 0.1% instilled in each eye twice daily.
AGN-195263 0.03%
1 drop of AGN-195263 0.03% instilled in each eye twice daily.
AGN-195263 0.01%
1 drop of AGN-195263 0.01% instilled in each eye twice daily.
AGN-195263 Vehicle
1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
Ophthalmic Consultants Long Island, Rockville Centre
South Shore Eye Care, LLP, Wantagh
Rochester Ophthalmological Group, PC, Rochester
Virginia Eye Consultants, Norfolk
Cornerstone Eye Care, High Point
The Eye Associates of Manatee, LLP, Bradenton
Taustine Eye Center, Louisville
John-Kenyon American Eye Institute, New Albany
Wohl Eye Center, Bloomingdale
Lifelong Vision Foundation, Chesterfield
Comprehensive Eye Care, Ltd., Washington
Ophthalmology Associates, St Louis
Tauber Eye Center, Kansas City
Durrie Vision, Overland Park
University of Arkansas for Medical, Little Rock
University of Houston, College of Optometry, Houston
Vision Center of Texas, PA, Cedar Park
Centennial Eye Associates, Centennial
Colorado Eye Associates, PC, Colorado Springs
Focus Clinical Research, Salt Lake City
Stacy Smith, MD, PC, Salt Lake City
Cornea Consultants of Arizona, Phoenix
Sall Research Medical Center, Artesia
Lugene Eye Institute, Glendale
North Valley Eye Medical Group, Inc., Mission Hills
Scripps Clinic, La Jolla
Lakeside Vision Center, Irvine
Eye Research Foundation, Newport Beach
Orange County Ophthalmology Medical Group, Inc., Garden Grove
North Bay Eye Associates, Inc., Petaluma
Drs. Fine, Hoffman, and Packer, LLC, Eugene
Danbury Eye Physicians & Surgeons, PC, Danbury
Northern New Jersey Eye Institute, PA, South Orange
Lead Sponsor
Allergan
INDUSTRY